No connection

Search Results

FOLD vs OPCH

FOLD
Amicus Therapeutics, Inc.
BEARISH
Price
$14.47
Market Cap
$4.54B
Sector
Healthcare
AI Confidence
85%
OPCH
Option Care Health, Inc.
NEUTRAL
Price
$28.34
Market Cap
$4.45B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
FOLD
--
OPCH
22.32
Forward P/E
FOLD
17.67
OPCH
13.33
P/B Ratio
FOLD
16.41
OPCH
3.35
P/S Ratio
FOLD
7.16
OPCH
0.79
EV/EBITDA
FOLD
111.86
OPCH
13.38

Profitability

Gross Margin
FOLD
88.5%
OPCH
19.26%
Operating Margin
FOLD
8.61%
OPCH
6.24%
Profit Margin
FOLD
-4.28%
OPCH
3.67%
ROE
FOLD
-11.58%
OPCH
15.2%
ROA
FOLD
2.48%
OPCH
6.14%

Growth

Revenue Growth
FOLD
23.7%
OPCH
8.8%
Earnings Growth
FOLD
-95.5%
OPCH
1.3%

Financial Health

Debt/Equity
FOLD
1.61
OPCH
0.96
Current Ratio
FOLD
2.84
OPCH
1.52
Quick Ratio
FOLD
1.72
OPCH
0.9

Dividends

Dividend Yield
FOLD
--
OPCH
--
Payout Ratio
FOLD
0.0%
OPCH
0.0%

AI Verdict

FOLD BEARISH

FOLD exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational deterioration. While the company maintains impressive gross margins (88.5%) and revenue growth (23.7%), these are offset by a catastrophic collapse in earnings growth (-95.5% YoY) and negative ROE. The stock is currently trading at a 52-week high despite a bearish technical trend score (10/100) and aggressive insider selling by the CEO and other officers. The disconnect between the current price and the underlying deterministic health metrics suggests a high risk of a price correction.

Strengths
Exceptional gross margins of 88.50%
Strong year-over-year revenue growth of 23.70%
Robust short-term liquidity with a current ratio of 2.84
Risks
Critically low Piotroski F-Score (2/9) signaling financial instability
Severe earnings growth decline of -95.50% YoY
Heavy insider selling with 11 sell transactions and 0 buys
OPCH NEUTRAL

OPCH exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust operational efficiency. However, the stock is trading at a significant premium to its Graham Number ($15.54) and Intrinsic Value ($11.37), suggesting a valuation disconnect based on defensive metrics. While analysts maintain a 'strong_buy' rating with a target of $40.09, this optimism is countered by bearish insider selling and a completely bearish technical trend. The outlook is balanced between strong balance sheet health and an overextended valuation relative to current earnings growth.

Strengths
Strong Piotroski F-Score (7/9) indicating high financial health
Healthy ROE of 15.20% and ROA of 6.14%
Attractive Price/Sales ratio of 0.79
Risks
Significant overvaluation relative to Graham and Intrinsic value models
Bearish insider sentiment with recent selling activity
Negative technical trend (0/100)

Compare Another Pair

FOLD vs OPCH: Head-to-Head Comparison

This page compares Amicus Therapeutics, Inc. (FOLD) and Option Care Health, Inc. (OPCH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile